2024

1. Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol

   Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

2. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study

   The Lancet Infectious Diseases, Vol. 24, Núm. 8, pp. 817-828

3. Short- and mid-term morbidity and primary-care burden due to infant respiratory syncytial virus infection: A Spanish 6-year population-based longitudinal study

   Pediatric Allergy and Immunology, Vol. 35, Núm. 5